Whitepaper
16 Oct 2023

Small Molecule APIs: Aligning Drug Strategy with Partnering Strategy

PDF 651 kB

Getting drugs to market faster and more economically is prompting new drug product development strategies to support better business and patient outcomes. Development of critical drug substances, particularly novel small molecule active pharmaceutical ingredients (APIs), is now being turned over to outsourced partners who have become the integral, primary drivers of the product’s overall development and go-to-market strategy.

Content provided by our supplier

Pfizer CentreOne

  • US
  • 2015
    On CPHI since
  • 50 - 99
    Employees
Company types
CMO/CDMO
Primary activities
Contract Manufacturer

Other Content from Pfizer CentreOne (6)

  • News An Altogether Different Kind of CDMO

    Discover what makes Pfizer CentreOne an Altogether Different Kind of CDMO.
  • Whitepaper Pfizer CentreOne: Ready to help meet your complex OSD needs, seamlessly and simply

    The production of oral solid dosage (OSD) forms is becoming increasingly complex as innovative techniques and technologies make it easier to harness challenging active pharmaceutical ingredients (APIs) in new medicines. Here we examine the key offerings a reliable CMDO partner must provide to successfully help support your OSD on its journey to market, and explore how Pfizer CentreOne can help.
  • News CPHI North America 2023: from the experts – Pfizer CentreOne

    Throughout CPHI North America (Philadelphia, PA; April 25–27, 2023), we caught up with some of the exhibiting organisations to ask what the show brings to the North American pharmaceutical sector, and what is driving industry innovation in this region of the world.  
  • Brochure Pfizer CentreOne Contract Manufacturing- General Capabilities

    Welcome to Pfizer CentreOne. We’re a global CDMO embedded within Pfizer and a leading supplier of specialty APIs. Working with our customers, we combine our technical and commercial knowledge with open dialogue to solve challenges – we call this intelligent collaboration.
  • News CPHI North America 2023 – From the Floor

    Follow along for live updates from the Content team as we bring you the latest from CPHI North America 2023 - from session talks, panel discussions, interviews, and more, there's a lot to discover with CPHI Online at the Pennsylvania Convention Center! 
  • Video The Music of Process Development Science

    Where QBD was the orchestral sheet music that determined how drug product development has been harmonized over the last 15 or so years, contemporary patient-centric risk-based approaches to drug development are the pop evolution. The music is still beautiful when produced well - but the focus is no longer on the full orchestra, it's on key players and moments. First - think McCartney and Lennon - one without the other and we don’t have the Beatles. The same can be said for collaboration between drug process development and commercial production colleagues. They are central to ensuring that products are easier to transfer and can be scaled, and that manufacturing challenges are identified early on and addressed proactively. In his keynote, Bernd Schümmelfeder Director-Team Leader PPD Business Development, Pfizer explores how lyrics (communication), rhythm (standardization), bass (structured development processes), and lead guitar (the use of smart technologies) throughout the drug development process come together to create beautiful music - a drug that gets to patients safely and at pace. Key areas for discussion include: Clear decision and inflection points to manage costs and prioritize projects with a higher probability of success Smart technologies like modeling to identify challenges early on and avoid late-stage pitfalls Use of platform technologies to simplify the tech transfer process and improve process robustness Areas to optimize the product development and manufacturing process to make it more efficient, cost-effective, and patient-focused